Puma Biotechnology (PBYI) Cash from Investing Activities Growth (3y) (2014 - 2026)
Powered by 
Analysis
Puma Biotechnology (PBYI) Cash from Investing Activities Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -53.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.84% |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn | 54.70% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.70% |
| Mar 31, 2026 | 28.90% |
| Dec 31, 2025 | -31.47% |
| Sep 30, 2025 | -60.15% |
| Jun 30, 2025 | -96.89% |
| Mar 31, 2025 | -44.55% |
| Dec 31, 2024 | -35.76% |
| Sep 30, 2024 | 27.20% |
| Jun 30, 2024 | 28.52% |
| Mar 31, 2024 | -53.25% |
| Dec 31, 2023 | -40.18% |
| Sep 30, 2023 | 85.04% |
| Jun 30, 2023 | 20.21% |
| Mar 31, 2023 | -35.86% |
| Dec 31, 2022 | -201.78% |
| Sep 30, 2022 | -41.01% |
| Jun 30, 2022 | -43.73% |
| Mar 31, 2022 | 30.09% |
| Dec 31, 2021 | 21.41% |
| Sep 30, 2021 | 40.63% |